I agree 20, but my gut-feeling is that Glaxo will be the incumbent Lani licensee. If this is the case, it's not necessarily going to be a worse deal than it could be with Roche...we'll know soon enough.
Again, if Glaxo is the incumbent, I'd hope there would have been early negotiations with Roche in order to use this as a bargaining chip with Glaxo.
- Forums
- ASX - By Stock
- BTA
- new uk deal for relenza
new uk deal for relenza, page-8
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)